SEC Form 4 · accession 0001728746-26-000014
MapLight Therapeutics, Inc. · MPLT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Woodruff Lillie
Officer — Chief Scientific Officer
Period of report
Aug 3, 2026
Accepted (ET)
Aug 4, 2026 · 8:39 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770069
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Voting Common StockF2 | Aug 3, 2026 | S | 22,082 | $12.54 | D | 202,380 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.12 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.